Riociguat for the treatment of pulmonary arterial hypertension

New England Journal of Medicine

Volumn 369, Issue 4, 2013, Pages 330-340

  Ghofrani, Hossein Ardeschir ^a,d   Galiè, Nazzareno ^e   Grimminger, Friedrich ^a   Grünig, Ekkehard ^b   Humbert, Marc ^g   Jing, Zhi Cheng ^h   Keogh, Anne M ⁱ   Langleben, David ^j   Kilama, Michael Ochan ^f   Fritsch, Arno ^c   Neuser, Dieter ^c   Rubin, Lewis J ^k  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c BAYER PHARMA AG   (Germany)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f Clinical Development Consultant   (Italy)

^g BICÊTRE HOSPITAL   (France)

^h FUWAI HOSPITAL   (China)

ⁱ ST VINCENT S HOSPITAL   (Australia)

^j MCGILL UNIVERSITY   (Canada)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ENDOTHELIN RECEPTOR ANTAGONIST; PLACEBO; PROSTANOID; RIOCIGUAT;

ACUTE KIDNEY FAILURE; ADULT; ANASARCA; ANEMIA; ARTICLE; BORG DYSPNEA SCALE; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; ESOPHAGUS DISEASE; ESOPHAGUS PAIN; ESOPHAGUS SWELLING; EXERCISE TOLERANCE; FAINTNESS; FATIGUE; FEMALE; FLUSHING; FUNCTIONAL STATUS; GASTRITIS; GASTROESOPHAGEAL REFLUX; HEART PALPITATION; HEART RIGHT VENTRICLE FAILURE; HUMAN; HYPOTENSION; LUNG VASCULAR RESISTANCE; MALE; MULTICENTER STUDY; NAUSEA; NECK PAIN; NOSE OBSTRUCTION; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PRESYNCOPE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCORING SYSTEM; SIDE EFFECT; SUPRAVENTRICULAR TACHYCARDIA; SWELLING; TACHYCARDIA; THORAX PAIN; VOMITING;

EID: 84880721470     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1209655     Document Type: Article

References (25)

1. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-537. [Erratum, Eur Heart J 2011;32:926.]
2. Schermuly RT, Ghofrani H-A, Wilkins MR, Grimminger F. Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol 2011;8:443-55.
3. Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL registry. Chest 2012;142:448-56.
4. Ghofrani H-A, D'Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013;369:319-29.
5. Grimminger F, Weimann G, Frey R, et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J 2009;33:785-92.
6. Stasch JP, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 2011;123:2263-73.
7. Ghofrani H-A, Hoeper MM, Halank M, et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J 2010;36:792-9.
8. Gabler NB, French B, Strom BL, et al. Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation 2012;126: 349-56.
9. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009;119: 2250-94. [Erratum, Circulation 2009; 120(2):e13.]
10. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000;161:487-92. (Pubitemid 30129457)
11. Galiè N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A metaanalysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009;30:394-403.
12. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-301. (Pubitemid 26033085)
13. Galiè N, Ghofrani H-A, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57. [Erratum, N Engl J Med 2006;354:2400-1.] (Pubitemid 41653106)
14. Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117:3010-9.
15. Galiè N, Brundage BH, Ghofrani H-A, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119:2894-903. [Erratum, Circulation 2011; 124(10):e279.]
16. Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347:322-9. (Pubitemid 34815354)
17. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896- 903. [Erratum, N Engl J Med 2002;346:1258.]
18. Mathai SC, Puhan MA, Lam D, Wise RA. The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2012;186:428-33.
19. Gilbert C, Brown MC, Cappelleri JC, Carlsson M, McKenna SP. Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil. Chest 2009;135:137-42.
20. Galiè N, Simonneau G, Barst RJ, Badesch D, Rubin L. Clinical worsening in trials of pulmonary arterial hypertension: results and implications. Curr Opin Pulm Med 2010;16:Suppl 1:S11-S19.
21. Lang M, Kojonazarov B, Tian X, et al. The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. PLoS One 2012;7(8):e43433.
22. Schermuly RT, Stasch JP, Pullamsetti SS, et al. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J 2008;32:881-91.
23. Dumitrascu R, Weissmann N, Ghofrani H-A, et al. Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation 2006;113:286-95.
24. Geschka S, Kretschmer A, Sharkovska Y, et al. Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats. PLoS One 2011;6(7):e21853.
25. Sharkovska Y, Kalk P, Lawrenz B, et al. Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models. J Hypertens 2010; 28:1666-75.